Sirion Biotech GmbH

  • Land: Deutschland

Nachricht vom 27.04.2015 | 16:49

Viral Vector Technologies from Europe directly accessible in Boston

(DGAP-Media / 2015-04-27 / 16:49)

27 April 2015

Viral Vector Technologies from Europe directly accessible in Boston

Munich based SIRION Biotech about to open office and lab in Boston Massachusetts

München, 27 April 2015, another Germany company from within its highly innovative life science industry expands into the North American markets, SIRION Biotech in Munich. The company is a leader in the field of viral vectors.

Viral vectors (or virus vectors) are a tool commonly used by molecular biologists to deliver genetic material into cells. This technique enables research of gene function and innovative therapeutics designed to correct defective genes and cancer. These technologies also assist in the discovery of new drug, food and cosmetic compounds. Of particular interest are viral vectors in vaccine development such as tumor treatment vaccines.

The company has gained market positions in German speaking countries, Japan, Korea and Israel. It grows fast at a rate of 40% p.a.. Interestingly, the US remains a challenge despite a common belief that similar cultural heritage and technical curiosity should allow for easy market access. Generating new customers is difficult, despite outstanding quality services. Setting up and managing complex project processes and keeping everyone updated, all these developments occur too far away for the Europe based contact. Despite internet and webinars, a sense of distance remains .

SIRION Biotech has over the last 2 years been recruiting and training binational professionals that are now on their way to Boston to establish a physical presence in the US. Boston has a large local market potential and time difference to Europe is only six hours: project inquiries come in in the afternoon, are being discussed with the Europe HQ first thing in the morning, project proposals and quotes are out with potential clients no later than 24 hours. Service levels realized in Europe can thus be offered to US clients as well.


About SIRION Biotech

SIRION Biotech started in Munich in 2007 with the idea of enabling novel cell models closer to reality than ever before. This required the assembly of an all-encompassing, novel viral vector platform. Both, designing de novo viral vectors and the subsequent creation of custom cell models will pave the way for superior compound development in the life sciences. SIRION's technologies have been validated in over 500 single projects with more than 150 academic and industrial partners. As a result, cell models for drug discovery and development have become highly reliable, as have the use of new viral vectors in gene therapy and vaccine studies both for research and clinical studies.

Contact SIRION Biotech USA:
Dr. Carl Christel
PO Box 3
Durham, NH 03824
Tel.: +1-(857) 284 1844


End of Media Release

Issuer: Sirion Biotech GmbH
Key word(s): Services

2015-04-27 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at and

349225  2015-04-27 

Interview im Fokus

„Bitcoin kurz vor dem Durchbruch“

Die Northern Bitcoin AG verzeichnet nicht nur ein rasantes Wachstum als führender Bitcoin-Miner, die Frankfurter betreiben auch einen klimaneutralen Bitcoin-Mining-Pool. Die strategische Zusammenarbeit mit der Rawpool-Gruppe katapultiert Northern Bitcoin „in eine völlig neue Dimension“, ist CEO Mathis Schultz überzeugt: „Der Bitcoin wird die Welt dramatisch verändern. Wir sehen uns exzellent aufgestellt, um in den kommenden Jahren als Pionier das führende europäische Unternehmen im Bereich Bitcoin-Blockchain aufzubauen.“


BIG Blockchain Intelligence Group: Coverage Initiated mit Kaufen-Rating

BIG Blockchain Intelligence Group Inc. bietet Software-Lösungen an, die eine Echtzeitüberprüfung von blockchainbasierten Transaktionen mit Hilfe von Such- und Analysefunktionen ermöglicht. Zur Kernkompetenz gehört eine Software, die zur Generierung von Daten aus Blockchain-Transaktionen verwendet wird. Aktuell konzentriert sich BIG auf Transaktionen von Kryptowährungen und bedient seine Kunden wie Regierungen, Strafverfolgungsbehörden, Banken und Finanzdienstleistern oder E-Commerce-Anbieter mit entsprechender Sicherheitstechnologie. Bei einem Kursziel von 1,03 CAD (0,69 €) lautet das Rating KAUFEN.

News im Fokus

Fresenius SE & Co. KGaA: Fresenius bestätigt und konkretisiert Konzernausblick für das Geschäftsjahr 2018

16. Oktober 2018, 23:09

Aktuelle Research-Studie

Homes & Holiday AG

Original-Research: Homes & Holiday AG (von GBC AG): Vorstandsinterview

17. Oktober 2018